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Colchicine After
Pulmonary Vein Isolation to
Prevent the Early Recurrence
of Atrial Fibrillation
Mollifying an Inflammatory Response?*
Gregory M. Marcus, MD, MAS,
Jonathan C. Hsu, MD
San Francisco, California
Atrial fibrillation (AF) is the most common arrhythmia and
is associated with a high risk of stroke and an increased risk
of death (1). Although an association between AF and
inflammation is now well established, the cause-and-effect
relationship remains incompletely understood (2,3). Previ-
ous studies have demonstrated that increased inflammation
may precede AF (4,5), supported by evidence that genetic
variants related to inflammatory processes may be more
prevalent in AF patients (6,7). Conversely, we and others
have shown that AF itself may contribute to an inflamma-
tory state (8–11).
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AF likely represents a final common pathway stemming
from multiple subtypes. Identifying AF patients with an
inflammation-based subtype is important in selecting can-
didates for anti-inflammatory therapies. In some cases,
inflammation-based subtypes already are apparent. For ex-
ample, building on the sterile pericarditis canine model (12)
and observational cardiac surgery studies (13), trials aimed
at decreasing inflammation after cardiac surgery with either
steroids (14) or colchicine (15) have shown reductions in
post-operative AF.
Left atrial catheter ablation to electronically isolate the
pulmonary veins now is commonplace for treatment of
symptomatic AF (16). Despite ongoing improvements in
the procedure, early recurrence after AF ablation (ERAF)
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this paper to disclose.often occurs (17). The cause of ERAF remains unknown,
but may involve an inflammatory response to thermal injury,
pericarditis, or both (18). Because ERAF likely portends a
higher risk of late recurrence, it is of particular interest
(19,20). Three days of corticosteroid administration after
AF ablation reduced immediate recurrence of AF (3 days
after the procedure) and longer-term AF recurrence (21).
However, potentially because of the short course of drug
administration, a reduction in AF recurrence between 4 and
30 days was not observed. A longer course of steroids may
not be prudent given the risk of adverse effects. We
previously showed that the inflammation resulting from AF
ablation may persist for more than 1 month (22), suggesting
that a longer course of an anti-inflammatory agent may be
necessary to combat ERAF.
In this issue of the Journal, Deftereos et al. (23) report
their findings after randomizing 170 paroxysmal AF pa-
tients undergoing pulmonary vein isolation with radiofre-
quency catheter ablation to 0.5 mg of twice daily colchicine
versus placebo. After 3 months of treatment, ERAF was
observed in a statistically significantly smaller 16% of those
receiving colchicine versus 34% of those receiving placebo.
The study has several strengths. As a blinded and
randomized study, the study addressed both known and
unknown confounders in an optimal fashion. All patients
had paroxysmal AF and all underwent a similar procedure.
Vaughn-Williams class I and III antiarrhythmic drugs were
not allowed. The colchicine group exhibited significantly
lower levels of both C-reactive protein and interleukin 6 by
day 4. After adding these markers into a multivariate model,
the hazard ratio for colchicine as a predictor of recurrent AF
was substantially attenuated. Statistically, this suggests that
the effect of colchicine on ERAF was at least in part
explained by decreased inflammation. This study likely
provides the strongest evidence to date that inflammation is
causal in ERAF after ablation.
There are several details worth considering before extend-
ing the regular use of post-ablation colchicine to clinical
practice. First, the best dose and duration of colchicine
remain unknown. Because the primary rationale for the
procedure remains quality-of-life improvement, we should
avoid replacing one problem (AF) with another (such as
gastrointestinal upset, observed in more of those receiving
colchicine). Although no serious adverse events were attrib-
uted to colchicine, monitoring for both liver toxicity and
myelotoxicity occurred. One case of transaminase elevation
requiring cessation of colchicine was required. The duration
of drug administration was based on our previous findings
regarding post-ablation C-reactive protein elevation, mea-
sured a median of 49 days after the procedure (interquartile
range: 37 to 93 days) (22). It seems that the trial investiga-
tors based the 3-month duration of treatment on the 75th
percentile of that range. It is possible that a shorter duration
would suffice. Discontinuing colchicine for intolerance or
adverse reaction before 1 month of therapy was rare,
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The as yet unanswered question is whether reduction in
ERAF will translate into long-term success. It is likely that
ERAF represents 2 different groups: those in whom the
procedure simply failed versus those with inflammation-
induced AF who are destined for success. If these processes
are entirely separate, prevention of ERAF may have no
bearing on late recurrence. However, it remains possible
that ERAF contributes to adverse remodeling, promoting
AF in the long term. A trial with longer follow-up is
necessary to determine if such inflammation-related remod-
eling is important.
In conclusion, the authors provide a valuable contribution
to the literature regarding post-ablation AF and perhaps AF
in general. The study provides strong evidence that inflam-
mation is sufficient to induce ERAF after pulmonary vein
isolation using radiofrequency catheter ablation and that
administration of colchicine may provide a safe and effective
strategy to reduce ERAF. Future studies will be important
to determine the optimal dose and duration of colchicine as
well as to determine if these early effects lead to lasting
success.
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